Home » Newsletters » BioWorld Science

BioWorld Science

March 27, 1997

View Archived Issues

Company Profile: MetaMorphix

Company Profile: T Cell Sciences

Rhone-Poulenc Rorer's Granocyte approved for additional indication

Millenium issued U.S. patents related to drug discovery

Alpha-adrenoceptor blockers from SKB

Allelix prepares PTH variants for osteoporosis

Evanston Hospital discloses radio- and chemosensitizers

NKA antagonists claimed by Zeneca

New anxiolytics from American Home Products

Diagnostic use of radiolabeled lisinopril derivatives disclosed by Merck Frosst

Bristol-Myers Squibb discovers new ribosome-inactivating protein

Sanofi discloses agents for treating CRF-related disorders

Hybridon announces year-end financial results for 1996

BioChem Pharma announces fourth-quarter and 1996 results

Noven discusses year-end results and 1997 outlook

OXiGENE reports 1996 financial results

Triangle Pharmaceuticals reports financial results

Xoma reports financial results for 1996

CoCensys reports 1996 fourth-quarter and year-end financial results

Therapeutic Antibodies announces results for the year ended December 31, 1996

U.S. timetable for Gadolite adjusted

Pharmacia & Upjohn seeks FDA approval for incontinence drug

CAT and Techniclone to initiate trials for tumor therapy

Novel orally active antithrombotic agent from Fuji Yakuhin

Armenian researchers describe novel antiarrhythmic agent

Theratechnologies reports development strategy for second GRF analogue

Antiplatelet 5-HT2A receptor antagonist characterized by Toa Eiyo

Update on NABI's HIV-IG clinical trials

Kaken prepares broad-spectrum antiulcer agent

Cheung Laboratories initiates preclinicals of BPH treatment system

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 24, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 24, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.